Can Lucentis Improve Vision in Patients with Diabetic Macular Edema?
March 11, 2011
Genentech, a member of the Roche Group, announced yesterday that two-year results from a pivotal Phase III trial (RISE) showed patients with diabetic macular edema (DME) who received Lucentis® (ranibizumab injection) experienced rapid and sustained improvement in vision compared to those who received a placebo (sham) injection. Improvement in vision was sustained for two years as demonstrated via eye chart reading scores at defined intervals.
There are presently no FDA-approved medicines to treat DME. However, Roche recently received approval from the European regulatory body to market Lucentis for the treatment of visual impairment due to DME.
Click here to read Roche’s press release.
Jump down to form below to submit your own comments